Note: Descriptions are shown in the official language in which they were submitted.
,
CA 2753513 2017-04-04
1
TITLE: COMPOUNDS AND METHODS FOR TREATING CANCER AND
VIRAL INFECTIONS
FIELD OF THE APPLICATION
[0002] The present application relates to methods for treating cancer and
viral infections.
BACKGROUND OF THE APPLICATION
[0003] Cancer is a class of diseases in which a group of cells display
uncontrolled
growth or division, invasion and sometimes metastasis. Most cancers form a
tumour, but
some, like leukemia, do not.
[0004] Treatments for viral infections have come to the forefront in view of
the recent
worldwide scare with H1N1 viral infections.
SUMMARY OF THE APPLICATION
[0005] Current chemotherapeutics affect only a small time zone during the cell
division
cycle. Typically, these drugs have cell kills of 2-5% in the active division
cycle. The
average cell division time in solid tumors is 90 to 120 days, in lymphomas,
about 30
days, in leukemias, about 5 to 6 days. In solid tumors about 90% of the cells
are in Go.
DNA synthesis is directly related to the speed of the cell cycle and
correlates with the
speed of ingestion of the amino acids into the DNA. By binding to amino acids,
the
compounds of the present application interfere with DNA synthesis and result
in an
effective treatment for cancer and viral infections.
[0006] Accordingly, the present application includes a method of treating
cancer
comprising administering to a subject in need thereof, an effective amount one
or more
compounds of Formula I, or pharmaceutically acceptable solvates or prodrugs
thereof:
wwwo _________________________________________
CA 02753513 2011-08-24
WO 2010/099600
PCT/CA2010/000281
2
0
R1-1(
N - (CH2),C(0)H
R2 (I)
wherein
RI is selected from Ci_6alkyl, phenyl and naphthyl;
R2 is selected from H and C(0)-R3 and R3 is selected from Ci_oalkyl, phenyl
and naphthyl
or R3 and RI are linked to form, together with the atoms to which they are
attached, a 5-
or 6-membered ring that is optionally fused to a phenyl or naphthyl group;
n is 1, 2, 3 or 4; and
when R2 is H, and n is 2, 3 or 4, the compound of Formula I optionally exists
in cyclized
form:
0
R1A OH
Nan:
wherein m is 1, 2 or 3.
[0007] The present application also includes a use of one or more compounds
Formula I,
as defined above, or pharmaceutically acceptable solvates or prodrugs thereof,
for
treating cancer. Further, the present application includes a use of one or
more compounds
of Formula I, as defined above, or pharmaceutically acceptable solvates or
prodrugs
thereof, to prepare a medicament for treating cancer. Still further, the
present application
includes one or more compounds of formula I as defined above, or
pharmaceutically
acceptable solvates or prodrugs thereof, for use to treat cancer.
[0008] The present application includes a method of treating or preventing a
viral
infection comprising administering to a subject in need thereof, an effective
amount of
one or more compounds Formula I, or pharmaceutically acceptable solvates or
prodrugs
thereof:
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
3
0
N-(CH2)õC(0)H
R2 (I)
wherein
RI is selected from Ci_6alkyl, phenyl and naphthyl;
R2 is selected from H and C(0)-R3 and R3 is selected from Ci_6alkyl, phenyl
and naphthyl
or R3 and RI are linked to form, together with the atoms to which they are
attached, a 5-
or 6-membered ring that is optionally fused to a phenyl or naphthyl group;
n is 1, 2, 3 or 4; and
when R2 is H, and n is 2, 3 or 4, the compound of Formula I optionally exists
in cyclized
form:
0
R1A OH
L4-4 m
wherein m is 1, 2 or 3.
[0009] The present application also includes a use of one or more compounds of
Formula
I, as defined above, or pharmaceutically acceptable solvates or prodrugs
thereof, for
treating or preventing a viral infection. Further, the present application
includes a use of
one or more compounds of Formula I, as defined above, or pharmaceutically
acceptable
solvates or prodrugs thereof, to prepare a medicament for treating or
preventing a viral
infection. Still further, the present application includes one or more
compounds of
formula I as defined above, or pharmaceutically acceptable solvates or
prodrugs thereof,
for use to treat or prevent a viral infection.
[0010] In an embodiment of the application the compounds of the application
are
administered to the subject over an extended period of time (i.e. long term or
chronic
administration).
100111 Other features and advantages of the present application will become
apparent
from the following detailed description. It should be understood, however,
that the
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
4
detailed description and the specific examples while indicating preferred
embodiments of
the application are given by way of illustration only, since various changes
and
modifications within the spirit and scope of the application will become
apparent to those
skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[09121 The application will now be described in relation to the drawings in
which:
[0013] Figure 1 shows the results of the evaluation of human U373 and SI-ISY5Y
cells
following extended incubation with compound I(a) compared to a control. Cells
were
seeded in 96-well plates following incubation with the indicated concentration
of
compound I(a) for 14, 21 or 28 days. Cells incubated in the absence of
compound for the
same number of days served as controls. Mean absorbance values from eight
wells are
expressed as fold changes relative to control with the relative degree of
variability
between the samples indicated as error bars. * p<0.05, ** p<0.01, # p<0.001,
Students t-
test.
DETAILED DESCRIPTION OF THE APPLICATION
(I) DEFINITIONS
100141 The term "alkyl" as used herein means straight and/or branched chain
alkyl
groups and includes methyl, ethyl, propyl, isopropyl, t-butyl, pentyl, hexyl
and the like.
[0015] A phthalimido group is represented by the following formula:
0
1:1101
0
[0016] In a naphthalimido group, an additional phenyl ring is fused to the
phenyl ring of
the phthalimido group.
[0017] The term "compounds of the application" as used herein refers to a
compound of
Formula I, or pharmaceutically acceptable solvates or prodrugs thereof It is
to be clear
that the methods and uses of the present application includes pharmaceutically
acceptable
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
solvates or prodrugs of compounds of the application and mixtures comprising
two or
more of compounds of Formula I, pharmaceutically acceptable solvates of
compounds of
Formula I or pharmaceutically acceptable prodrugs of compounds of Formula I.
[0018] The term "pharmaceutically acceptable" means compatible with the
treatment of
animals, in particular, humans.
[0019] The term "solvate" as used herein means a compound of the Formula I,
wherein
molecules of a suitable solvent are incorporated in the crystal lattice. A
suitable solvent
is physiologically tolerable at the dosage administered. Examples of suitable
solvents are
ethanol, water and the like. When water is the solvent, the molecule is
referred to as a
"hydrate". The formation of solvates of the compounds of the application will
vary
depending on the compound and the solvate. In general, solvates are formed by
dissolving the compound in the appropriate solvent and isolating the solvate
by cooling
or using an antisolvent. The solvate is typically dried or azeotroped under
ambient
conditions.
[0020] Compounds of the application include prodrugs. In general, such
prodrugs will
be functional derivatives of a compound of the application which are readily
convertible
in vivo into the compound from which it is notionally derived. In an
embodiment of the
application, prodrugs of the compounds of the application may be conventional
esters
formed with available hydroxy or amino groups. For example, an available OH or
NH
group in a compound of the invention may be acylated using an activated acid
in the
presence of a base, and optionally, in inert solvent (e.g. an acid chloride in
pyridine).
Some common esters which have been utilized as prodrugs are phenyl esters,
aliphatic
(C8-C24) esters, acyloxymethyl esters, carbamates and amino acid esters. In
further
embodiments, the prodrugs of the compounds of the invention are those in which
one or
more of the hydroxy groups in the compounds is masked as groups which can be
converted to hydroxy groups in vivo. In a further embodiment, prodrugs of the
compounds of the application are conventional imines, oximes, acetals, enol
esters,
oxazolidines or thiazolidines formed with the available aldehyde group.
Conventional
procedures for the selection and preparation of suitable prodrugs are
described, for
CA 02753513 2011-08-24
WO 2010/099600
PCT/CA2010/000281
6
example, in "Design of Prodrugs" ed. H. Bundgaard, Elsevier, 1985 or are known
to a
person skilled in the art.
[0021] The term "subject" as used herein includes all members of the animal
kingdom
including human. The subject is suitably a human.
[0022] The term a "therapeutically effective amount", "effective amount" or a
"sufficient
amount" of a compound of the present application is a quantity sufficient to,
when
administered to the subject, including a mammal, for example a human, effect
beneficial
or desired results, including clinical results, and, as such, an "effective
amount" or
synonym thereto depends upon the context in which it is being applied. For
example, in
the context of disease, therapeutically effective amounts of the compounds of
the present
disclosure are used to treat, modulate, attenuate, reverse, or affect cancer
or a viral
infection in a mammal. An "effective amount" is intended to mean that amount
of a
compound that is sufficient to treat or inhibit the cancer or viral infection
or a disease
associated with the cancer or viral infection. The amount of a given compound
of the
present disclosure that will correspond to such an amount will vary depending
upon
various factors, such as the given drug or compound, the pharmaceutical
formulation, the
route of administration, the type of disease or disorder, the identity of the
subject or host
being treated, and the like, but can nevertheless be routinely determined by
one skilled in
the art. Also, as used herein, a "therapeutically effective amount" of a
compound of the
present application is an amount which inhibits, suppresses or reduces a
cancer or viral
infection (e.g., as determined by clinical symptoms or the amount of cancer or
virus) in a
subject as compared to a control. As defined herein, a therapeutically
effective amount
of a compound of the present application may be readily determined by one of
ordinary
skill by routine methods known in the art.
[0023] As used herein, and as well understood in the art, "treating" or
"treatment" is an
approach for obtaining beneficial or desired results, including clinical
results. Beneficial
or desired clinical results can include, but are not limited to, alleviation
or amelioration
of one or more symptoms or conditions, diminishment of extent of disease,
stabilized
(i.e. not worsening) state of disease, preventing spread of disease, delay or
slowing of
CA 02753513 2011-08-24
WO 2010/099600
PCT/CA2010/000281
7
disease progression, amelioration or palliation of the disease state, and
remission
(whether partial or total), whether detectable or undetectable. "Treatment"
can also mean
prolonging survival as compared to expected survival if not receiving
treatment.
[0024] Moreover, a "treatment" or "prevention" regime of a subject with a
therapeutically effective amount of the compound of the present application
may consist
of a single administration, or alternatively comprise a series of
applications. For
example, the compound of the present application may be administered at least
once a
week. However, in another embodiment, the compound may be administered to the
patient from about one time per week to one or more, for example one to four,
times
daily for a given treatment. The length of the treatment or prevention period
depends on
a variety of factors, such as the severity of the disease, the age of the
patient, the
concentration and the activity of the compounds of the present application, or
a
combination thereof. It will also be appreciated that the effective dosage of
the
compound used for the treatment or prevention may increase or decrease over
the course
of a particular treatment or prophylaxis regime. Changes in dosage may result
and
become apparent by standard diagnostic assays known in the art. In some
instances,
chronic administration may be required. The compounds of the present
application may
be administered before, during or after exposure to the virus or to detection
or formation
of the cancer.
[0025] "Palliating" a disease or disorder, means that the extent and/or
undesirable
clinical manifestations of a disorder or a disease state are lessened and/or
time course of
the progression is slowed or lengthened, as compared to not treating the
disorder.
[0026] The term "prevention" or "prophylaxis", or synonym thereto, as used
herein
refers to a reduction in the risk or probability of a patient becoming
afflicted with a viral
infection or manifesting a symptom associated with a viral infection.
[0027] In understanding the scope of the present disclosure, the term
"comprising" and
its derivatives, as used herein, are intended to be open ended terms that
specify the
presence of the stated features, elements, components, groups, integers,
and/or steps, but
do not exclude the presence of other unstated features, elements, components,
groups,
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
8
integers and/or steps. The foregoing also applies to words having similar
meanings such
as the terms, "including", "having" and their derivatives. Finally, terms of
degree such as
"substantially", "about" and "approximately" as used herein mean a reasonable
amount of
deviation of the modified term such that the end result is not significantly
changed. These
terms of degree should be construed as including a deviation of at least 5%
of the
modified term if this deviation would not negate the meaning of the word it
modifies.
(II) THERAPEUTIC METHODS AND USES
[0028] The present application includes a method of treating cancer comprising
administering to a subject in need thereof, an effective amount of one or more
compounds of Formula 1, or pharmaceutically acceptable solvates or prodrugs
thereof:
0
Rl
N ¨(c H2)õc(0)H
R2 (I)
wherein
RI is selected from Ci_6alkyl, phenyl and naphthyl;
R2 is selected from H and C(0)-R3 and R3 is selected from C1_6a1ky1, phenyl
and naphthyl
or R3 and RI are linked to form, together with the atoms to which they are
attached, a 5-
or 6-membered ring that is optionally fused to a phenyl or naphthyl group;
n is 1, 2, 3 or 4; and
when R2 is H, and n is 2 ,3 or 4, the compound of Formula I optionally exists
in cyclized
form:
0
OH
11\f'
L-44 m
wherein m is 1, 2 or 3.
[0029] It is an embodiment of the application that RI is selected from phenyl,
isobutyl,
isopropyl and t-butyl. In a further embodiment RI is t-butyl.
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
9
[0030] It is another embodiment of the application that RI and R3 are linked
to form,
together with the atoms to which they are attached, a 5- membered ring that is
fused to a
phenyl or naphthyl group to provide a phthalimido or a naphthalimido group. In
further
embodiment, RI and R3 are linked to form, together with the atoms to which
they are
attached, a phthalimido group.
[0031] In another embodiment of the application, n is 2 or 3. In a further
embodiment, n
is 3.
[0032] In another embodiment, R2 is H and the compound of Formula I exists in
cyclized
form:
0
R1 OH
1-4J m
wherein m is 2 or 3. In a further embodiment m is 2.
[0033] In a further embodiment of the present application, the compound of
Formula I is:
4-(1, 3-dioxo-1, 3-dihydro-2H-isoindo1-2-y1) butanal (Ia); or
tert-butyl 2-hydroxypyrrolidine- 1 -carboxylate, I(b), or
a pharmaceutically acceptable solvate or prodrug thereof.
[0034] The present application also includes a use of one or more compounds of
Formula
I, as defined above, or pharmaceutically acceptable solvates or prodrugs
thereof, for
treating cancer. Further, the present application includes a use of one or
more compounds
of Formula I, as defined above, or pharmaceutically acceptable solvates or
prodrugs
thereof, to prepare a medicament for treating cancer. Still further, the
present application
includes one or more compounds of Formula I, as defined above, or
pharmaceutically
acceptable solvates or prodrugs thereof, for use to treat cancer.
[0035] In an embodiment of the application, the cancer is any form of
neoplastic disease,
including both tumour forming and non-tumour forming cancers. In a further
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
embodiment, the cancer is a brain cancer. In a further embodiment the cancer
is a
neuroblastoma or an astrocytoma.
[0036] The present application includes a pharmaceutical composition for
treating cancer
comprising an effective amount of one or more of compounds of Formula I as
defined
above, or pharmaceutically acceptable solvates or prodrugs thereof, and a
pharmaceutically acceptable carrier.
100371 The present application also includes a method of treating or
preventing a viral
infection comprising administering to a subject in need thereof, an effective
amount of
one or more compounds of Formula I, or pharmaceutically acceptable solvates or
prodrugs thereof:
0
R1-1
N - (CH2),C(0)H
R2 (I)
wherein
R1 is selected from C1_6alkyl, phenyl and naphthyl;
R2 is selected from H and C(0)-R3 and R3 is selected from Ci_oalkyl, phenyl
and naphthyl
or R3 and RI are linked to form, together with the atoms to which they are
attached, a 5-
or 6-membered ring that is optionally fused to a phenyl or naphthyl group;
n is 1, 2, 3 or 4; and
when R2 is H, and n is 2 ,3 or 4, the compound of Formula I optionally exists
in cyclized
form:
0
RI OH
wherein m is 1, 2 or 3.
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
11
[0038] It is an embodiment of the application that RI is selected from phenyl,
isobutyl,
isopropyl and t-butyl. In a further embodiment R' is t-butyl.
100391 It is another embodiment of the application that RI and R3 are linked
to form,
together with the atoms to which they are attached, a 5- membered ring that is
fused to a
phenyl or naphthyl group to provide a phthalimido or a naphthalimido group. In
further
embodiment, RI and le are linked to form, together with the atoms to which
they are
attached, a phthalimido group.
[0040] In another embodiment of the application, n is 2 or 3. In a further
embodiment, n
is 3.
[0041] In another embodiment, R2 is H and the compound of Formula I exists in
cyclized
form:
0
R11( OH
m
wherein m is 2 or 3. In a further embodiment m is 2.
[0042] In a further embodiment of the present application, the compound of
Formula I is:
4-(1, 3-dioxo-1, 3-dihydro-2H-isoindo1-2-y1) butanal (Ia); or
tert-butyl 2-hydroxypyrrolidine-1-carboxylate, I(b), or
a pharmaceutically acceptable solvate or prodrug thereof.
[0043] The present application also includes a use of one or more compounds of
Formula
I, as defined above, or pharmaceutically acceptable solvates or prodrugs
thereof, for
treating or preventing a viral infection. Further, the present application
includes a use of
one or more compounds of Formula I, as defined above, or pharmaceutically
acceptable
solvates or prodrugs thereof, to prepare a medicament for treating or
preventing a viral
infection. Still further, the present application includes one or more
compounds of
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
12
Formula I as defined above, or pharmaceutically acceptable solvates or
prodrugs thereof,
for use to treat or prevent a viral infection.
[0044] In an embodiment of the application, the viral infection is an
influenza-type
infection. In a further embodiment, the viral infection is an influenza A
infection or an
influenza B infection.
[0045] The present application includes a pharmaceutical composition for
treating or
preventing a viral infection comprising an effective amount of one or more of
compounds of Formula I as defined above, or pharmaceutically acceptable
solvates or
prodrugs thereof, and a pharmaceutically acceptable carrier.
[0046] Some of the compounds of Formula I, as defined above, have at least one
asymmetric centre. Where the compounds possess one asymmetric centre, they
exist as
enantiomers. Where the compounds possess more than one asymmetric centre, they
exist
as diastereomers. It is to be understood that all such isomers and mixtures
thereof in any
proportion are encompassed within the scope of the present application. It is
to be
understood that while the stereochemistry of the compounds may be as provided
for in
any given compound listed herein, such compounds may also contain certain
amounts
(e.g. less than 20%, preferably less than 10%, more preferably less than 5%)
of
compounds of the invention having alternate stereochemistry.
[0047] In an embodiment of the present application, the compounds of Formula I
as
defined above, or pharmaceutically acceptable solvates or prodrugs thereof,
are prepared
from known starting materials using procedures known in the art. For example,
4,4-
diethooxybutan- 1-amine, which is commercially available is readily mono or
diacylated
using standard procedures. Conversion of the diethoxy group to the
corresponding
aldehyde is performed by treatment with acid and if, R2 is H, the resulting
compound will
typically cyclize in situ.
[0048] In some cases the chemistries outlined above may have to be modified,
for
instance by use of protective groups, to prevent side reactions due to
reactive groups,
such as reactive groups attached as substituents. This may be achieved by
means of
conventional protecting groups, for example as described in "Protective Groups
in
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
13
Organic Chemistry" McOmie, J.F.W. Ed., Plenum Press, 1973 and in Greene, T.W.
and
Wuts, P.G.M., "Protective Groups in Organic Synthesis", John Wiley & Sons,
1991.
[0049] In accordance with the methods and uses of the application, the
compounds of
Formula I, as defined above, and/or pharmaceutically acceptable solvates
and/or
prodrugs thereof, are administered to a patient in a variety of forms
depending on the
selected route of administration, as will be understood by those skilled in
the art. In an
embodiment, compounds of Formula 1, as defined above, and/or solvates and/or
prodrugs
thereof, are administered, by oral, parenteral, buccal, sublingual, nasal,
rectal, patch,
pump or transdermal administration and the pharmaceutical compositions
formulated
accordingly. Parenteral administration includes intravenous, intraperitoneal,
subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary,
intrathecal, rectal
and topical modes of administration. Parenteral administration may be by
continuous
infusion over a selected period of time. Conventional procedures and
ingredients for the
selection and preparation of suitable formulations are described, for example,
in
Remington's Pharmaceutical Sciences (2000 - 20th edition) and in The United
States
Pharmacopeia: The National Formulary (USP 24 NF19) published in 1999.
[0050] In an embodiment, compounds of Formula I, as defined above, and/or
solvates
and/or prodrugs thereof, are orally administered, for example, with an inert
diluent or
with an assimilable edible carrier, or are enclosed in hard or soft shell
gelatin capsules, or
are compressed into tablets, or are incorporated directly with the food of the
diet. For oral
therapeutic administration, the compound is incorporated, for example, with
excipient
and used in the form of ingestible tablets, buccal tablets, troches, capsules,
elixirs,
suspensions, syrups, wafers, and the like.
[0051] In another embodiment, compounds of Formula I, as defined above, and/or
solvates and/or prodrugs thereof, are administered parenterally. For example,
solutions of
a compound of the application are prepared in water suitably mixed with a
surfactant
such as hydroxypropylcellulose. In an embodiment, dispersions are prepared in
glycerol,
liquid polyethylene glycols, DMSO and mixtures thereof with or without
alcohol, and in
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
14
oils. Under ordinary conditions of storage and use, these preparations contain
a
preservative to prevent the growth of microorganisms.
[0052] The pharmaceutical forms suitable for injectable use include sterile
aqueous
solutions or dispersion and sterile powders for the extemporaneous preparation
of sterile
injectable solutions or dispersions. In all cases, the form must be sterile
and must be
fluid to the extent that easy syringability exists.
[0053] In a further embodiment, compositions for nasal administration are
conveniently
formulated as aerosols, drops, gels or powders. Aerosol formulations typically
comprise
a solution or fine suspension of the active substance in a physiologically
acceptable
aqueous or non-aqueous solvent and are usually presented in single or
multidosc
quantities in sterile form in a sealed container, which can take the form of a
cartridge or
refill for use with an atomising device. Alternatively, the sealed container
is a unitary
dispensing device such as a single dose nasal inhaler or an aerosol dispenser
fitted with a
metering valve which is intended for disposal after use. Where the dosage form
comprises an aerosol dispenser, it will contain a propellant which can be a
compressed
gas such as compressed air or an organic propellant such as
fluorochlorohydrocarbon.
The aerosol dosage forms can also take the form of a pump-atomizer.
[0054] In a further embodiment, compositions suitable for buccal or sublingual
administration include tablets, lozenges, and pastilles, wherein the active
ingredient is
formulated with a carrier such as sugar, acacia, tragacanth, or gelatin and
glycerine.
Compositions for rectal administration are conveniently in the form of
suppositories
containing a conventional suppository base such as cocoa butter.
[0055] In a further embodiment, compounds of Formula I, as defined above,
and/or
solvates and/or prodrugs thereof, are administered in the form of liposome
delivery
systems, such as small unilamellar vesicles, large unilamellar vesicles and
multilamellar
vesicles. Liposomes are, for example, formed from a variety of phospholipids,
such as
cholesterol, stearylamine or phosphatidylcholines.
[0056] In a further embodiment, compounds of Formula I, as defined above,
and/or
solvates and/or prodrugs thereof, are delivered by the use of monoclonal
antibodies as
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
individual carriers to which the compound molecules are coupled. In another
embodiment, compounds of Formula I. as defined above, and/or solvates and/or
prodrugs
thereof, are coupled with soluble polymers as targetable drug carriers. Such
polymers
include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-
phenol, polyhydroxy-ethylaspartamide-phenol, or
polyethy leneoxi de-poly ly sine
substituted with palmitoyl residues. In a further embodiment, compounds of
Formula I,
as defined above, and/or solvates and/or prodrugs thereof, are coupled to a
class of
biodegradable polymers useful in achieving controlled release of a drug, for
example,
polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic
acid,
polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters,
polyacetals,
polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block
copolymers of hydrogels.
[0057] In an embodiment, compounds of Formula I, as defined above, and/or
solvates
and/or prodrugs thereof, are used alone or in combination with other known
agents useful
for treating cancer.
100581 When used in combination with other agents useful in treating cancer,
compounds
of Formula I, as defined above, and/or solvates and/or prodrugs thereof, are
suitably
administered contemporaneously with those agents. As used herein,
"contemporaneous
administration" of two substances to a subject means providing each of the two
substances so that they are both biologically active in the individual at the
same time.
The exact details of the administration will depend on the pharmacokinetics of
the two
substances in the presence of each other, and can include administering the
two
substances within a few hours of each other, or even administering one
substance within
24 hours of administration of the other, if the pharmacokinetics are suitable.
Design of
suitable dosing regimens is routine for one skilled in the art. In particular
embodiments,
two substances will be administered substantially simultaneously, i.e., within
minutes of
each other, or in a single composition that contains both substances.
100591 The dosage of compounds of Formula I, as defined above, and/or solvates
and/or
prodrugs thereof, can vary depending on many factors such as the
pharmacodynamic
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
16
properties of the compound, the mode of administration, the age, health and
weight of the
recipient, the nature and extent of the symptoms, the frequency of the
treatment and the
type of concurrent treatment, if any, and the clearance rate of the compound
in the animal
to be treated. One of skill in the art can determine the appropriate dosage
based on the
above factors. In an embodiment, compounds of the application, and/or solvates
and/or
prodrugs thereof, are administered initially in a suitable dosage that is
adjusted as
required, depending on the clinical response. As a representative example,
oral dosages
of compounds of Formula I, as defined above, and/or solvates and/or prodrugs
thereof,
range between about 1 mg per day to about 400 mg per day for an adult,
suitably about 1
mg per day to about 200 mg per day, more suitably about 1 mg per day to about
20 mg
per day. When formulated for oral administration, the compounds are suitably
in the
form of tablets containing 0.25, 0.5, 0.75, 1.0, 5.0, 10.0, 20.0, 25.0, 30.0,
40.0, 50.0, 60.0,
70.0 75.0, 80.0, 90.0, 100.0 150, 200, 250, 300, 350 or 400 mg of active
ingredient per
tablet. Suitably, for oral administration, the compounds are suitably in the
form of
tablets containing 0.25, 0.5, 0.75, 1.0, 5.0 or 10.0, mg of active ingredient
per tablet. In
another embodiment, compounds of Formula I, as defined above, and/or solvates
and/or
prodrugs thereof, are administered in a single daily dose or the total daily
dose is divided
into two, three of four daily doses. If the compound of Formula I, as defined
above,
and/or solvates and/or prodrugs thereof, are to be administered transdermally,
using, for
example, those forms of transdermal skin patches that are well known to those
skilled in
the art, the dosage administration will be continuous rather than intermittent
throughout
the dosage range.
[0060] In an embodiment of the application, the compounds of Formula I, as
defined
above, and/or solvates and/or prodrugs thereof, are administered or used over
an
extended period of time, i.e. long term use or chronic use for both treating
cancer or
treating or preventing a viral infection. The term "long term" and "chronic"
use or
administration as used herein means that the compounds of Formula I, as
defined above,
and/or pharmaceutically acceptable solvates or prodrugs thereof, are
administered to a
subject on a continuous regular, long-term therapeutic basis. For example, the
compounds of Formula I, as defined above, and/or pharmaceutically acceptable
solvates
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
17
or prodrugs thereof, are administered to a subject without substantial
interruption, such
as, for example, daily, weekly, alternate days, alternate weeks, for a time
period of at
least several weeks or months to several years, for the purpose of treating
cancer in a
subject needing treatment. In an embodiment of the application, the compounds
of
Formula I, as defined above, and/or pharmaceutically acceptable solvates or
prodrugs
thereof, are administered to a subject for at least about 2 months. In a
further
embodiment of the application, the compounds of Formula I, as defined above,
and/or
pharmaceutically acceptable solvates or prodrugs thereof, are administered to
a subject
on an indefinite basis, for example until such administration does not have a
beneficial
effect or treatment.
EXAMPLES
EXAMPLE]: Synthesis of 4-(1, 3-dioxo-1, 3-dihydro-2H-isoindo1-2-y1) butanal
(Ia)
Step 1 of 3: Preparation of 2-(4,4-diethoxybutylcarbamoyl)benzoic acid
0 0
c
I. 0 + H2N H3 N r.(3*'=7CH3
0 0CH3 OH
0
100611 Materials:
(1) Phthalic Anhydride (Aldrich), 3.89 g (26.3 mmoles)
(2) 4,4-diethoxybutan-l-amine (Aldrich), 4.03 g (25.0 mmoles)
(3) N,N-dimethylaminopyridine (Aldrich), 30.5 mg (0.25 mmoles)
(4) Triethylamine (tech), 3.83 mL (27.3 mmoles)
(5) Tetrahyofuran (tech), 40.0 mL
[0062] To a dry 100 mL round bottom flask was added tetrahydrofuran (40.0
mL), N,N-dimethylpyridin-4-amine (4.03 g), N,N-dimethylaminopyridine (30.5 mg)
and
triethylamine (3.83 mL). The solution was cooled to below 10 C in an ice-
water bath.
Phthalic anhydride (3.89 g) was added portion-wise into the solution at below
10 C. A
CA 02753513 2011-08-24
WO 2010/099600
PCT/CA2010/000281
18
mild exotherm was observed. After addition, the solution was stirred at below
10 C for
half hour and them slowly warmed up to room temperature and stirring was
continued
for another hour. A small sample was taken and stripped to dryness under
vacuum at
room temperature. The residue was dissolved in CDC13 and a proton NMR spectrum
was
run. The result showed that complete conversion had been achieved. The
remaining
reaction mixture was stripped to dryness under vacuum at room temperature. The
crude
product was used directly for next step without further purification.
Step 2 of 3: Preparation of 2-(4,4-diethoxybuty1)-1H-isoindole-1,3(2H)-dione
00 0
0 (i)
NH
=
N CH3
OH 0\/CH3 0
0
[0063] Materials:
(1) Step 1 product (crude), 25.0 mmoles
(2) Acetic anhydride (tech), 35.0 mL
(3) Sodium acetate (tech), 1.0 g
(4) Ethyl acetate (tech), 60 mL
(5) Saturated Sodium bicarbonate, 30.0 mL
(6) Sodium sulfate (tech), 5.0 g
(7) Ice, 200g
[0064] Acetic anhydride (35.0 mL) and sodium acetate (1.0 g) were added
into
the residue from step. The slurry was heated to 110 C and stirred at this
temperature for
three hours. A small sample was quenched into a mixture of ethyl acetate and
saturated
sodium bicarbonate. The organic phase was separated and stripped to dryness.
The
residue was dissolved in CDCI3 and a proton NMR was run. The result showed
that
complete conversion had been achieved.
[0065] The remaining reaction solution was cooled to room temperature and
poured into an ice-water mixture (200 g). After stirring for about 2 hours,
the solution
CA 02753513 2011-08-24
WO 2010/099600
PCT/CA2010/000281
19
was extracted with ethyl acetate (3 x 20 mL). The combined organic phase was
washed
with saturated sodium bicarbonate (2 x 15 mL) and dried with sodium sulfate
(5.0 g).
The filtrate was stripped to dryness to give the crude product 2 in overall
90% yields for
step 1 and 2.
[0066] 11-1-NMR (CDC13): 7.85 (m, 21-1), 7.71 (m, 2H), 4.52 (t, 5.7 Hz, 1H),
3.72 (t,
7.2Hz, 2H), 3.62 (m, 2H), 3.50 (m, 2H), 1.76 (m, 2H), 1.66 (m, 2H) and 1.19
(t, 7.2 Hz,
6H).
Step 3 of 3: Preparation of 4-(1, 3-dioxo-1, 3-dihydro-2H-isoindo1-2-
yl)butanal, 1(a)
= N0 CH3
N()
=
0 0
[0067] Materials:
(1) Step 2 product (crude), 4.55g (15.6 mmoles)
(2) Tetrahyofuran (tech), 35.0 mL
(3) Toluenesulfonic acid mono hydrate (Aldrich), 150 mg
(4) Ethyl acetate (tech), 50 mL
(5) Saturated Sodium bicarbonate, 20.0 mL;
(6) Sodium sulfate (tech), 5.0 g
(7) Water, 3.5 mL
(8) Brine, 20 mL
[0068] To a 100 mL round bottom flask was added step 2 product (4.55g)
followed by adding tetrahydrofuran (35.0 mL), water (3.5 mL) and
toluenesulfonic acid
(150 mg). The solution was stirred at room temperature under nitrogen. The
reaction
progress was monitored by NMR. After three days a completed conversion had
been
achieved. The solution was diluted with ethyl acetate (50.0 mL) and washed
with
saturate sodium bicarbonate (20 mL), brine (20 mL) and dried with sodium
sulfate (5.0
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
g). The filtrate was stripped to dryness and gave the product I(a) in 86%
yield in over
90% purity based on NMR.
[0069] 11-1-NMR (CDC13): 9.78 (t, 1.2 H7, III), 7.85 ( m, 2H), 7.73 (m, 2H),
3.75 (t, 6.9
Hz, 2H), 2.55 (td, 6.9Hz, 1.2 Hz, 2H) and 2.03 (m, 2H).
Example 2: Synthesis of tert-butyl 2-hydroxypyrrolidine-1-carboxylate 1(b)
Step 1 of 2: Preparation of tert-butyl (4,4-diethoxybutyl)carbamate
H3cC3 1-13_5-1
(o3 cH3 o
H3C> 0 0 CH3 H21,4 I-11C )1,
0 N
0 0 0 0C1I3 0CH3
[0070] Materials:
(1) 4,4-diethoxybutan-1-amine (Aldrich), 16.125 g (0.100 moles)
(2) di-tert-butyl dicarbonate (Aldrich), 21.825 g (0.100 moles)
(3) Triethylamine (tech), 1.0 mL (7.2 mmoles)
(4) Tetrahyofuran (tech), 30.0 mL
[0071] To a dry 100 mI, round bottom flask was added tetrahydrofuran (30.0
mL), di-tert-butyl dicarbonate (21.825g) and triethylamine (1.0 mL). The
solution was
cooled to below 10 C in an ice-water batch. 4-Diethoxybutan- 1 -amine (16.125
g) was
added slowly into the solution at below 10 C. A mild exotherm was observed.
After
addition the solution was stirred at below 10 C for a half hour and them
slowly warmed
up to room temperature and stirring continued for 1.5 hours. An in-process QC
(TLC,
heptane: ethyl acetate, 7:3) showed a completed conversion had been achieved.
The
reaction was stripped to dryness under vacuum at room temperature. The crude
product
was used directly for next step without further purification. The yield was
quantitative.
The crude product was identified based on NMR data.
[0072] 1H-NMR (CDC13, ppm): 4.49 ( t, 5.1Hz, 1H), 3.64 (m, 2H), 3.49 (m, 2H),
3.14
(m, 211), 1.66 1.52 (m, 2H), 1.44 (s, 911) and 1.21 (t, 7.2Hz, 6H).
CA 02753513 2011-08-24
WO 2010/099600
PCT/CA2010/000281
21
Step 2 of 2: Preparation of tert-butyl 2-hydroxypyrrolidine- 1 -carboxylate,
I(b)
CH3O OH
CH3 0 0
CH3
H3C-71,,,,i1,N,0 CH-
H3C-71 N ,0 (INN-icy-1c
CH3
H3C
0CH3 H3C H CH3
[0073] Materials:
(1) Step 1 product (crude), 5.0 g (0.019 moles)
(2) Toluenesulfonic acid monohydrate (Aldrich), 0.150 g (0.79 mmoles)
(3) Tetrahyofuran (tech), 35.0 mL
(4) DI-water, 5.0 mL
(5) Saturated Sodium bicarbonate, 2.0 mL
(6) Sodium sulfate (tech), 2.0 g
(7) Ethyl acetate (tech), 20 mL
[0074] To a 50 mL
round flask, was added the step 1 product (5.0 g),
tetrahydrofuran (35.0 mL) and DI-water (5.0 mL). Toluenesulfonic acid
monohydrate
(0.150 g) was added and the solution was stirred at room temperature over
three hours. A
small sample was taken and stripped to dryness. The residue was dissolved in
CDC13 and
proton NMR was run. The result showed a completed conversion had been
achieved.
[0075] Saturated
sodium bicarbonate (2.0 mL) was added to the reaction and
tetrahydrofuran was stripped off under vacuum at room temperature. Ethyl
acetate (20.0
mL) was added to dissolve the residue. After removing the water phase, the
organic
phase was dried over sodium sulfate (2.0 g). The solids were filtered off and
the filtrate
was concentrated to dryness under vacuum at below 40 C to give the crude
product in
about 87% yield. The major compound from the crude product was identified
purely
based on NMR data.
[0076] 1H-NMR (CDC13, ppm): 5.48 ( m, 1H), 3.49 (m, 2H), 3.28 (m, 2H), 1.90
(m,
2H), 1.48 (s, 9H).
CA 02753513 2011-08-24
WO 2010/099600
PCT/CA2010/000281
22
Example 3: Evaluation of the activity of compounds in indicator human
neuroglioma and
neuroblastoma cell lines
[0077] Compound preparation: Stock solutions of test compounds were prepared
in
dimethylsulfoxide (DMSO) at 250 mg/ml. Working concentrations of 10 mg/ml were
subsequently prepared from the stock solution and stored in 50 pl aliquots at -
20 C until
used.
[0078] Cells and cell culture: Proof-of-principle studies in this example
focused on two
human brain cancer cell lines, namely SH-SY5Y neuroblastoma cells and 1J373
astroglioma cells. SH-SY5Y cells were derived from a metastatic bone tumour
from a
four year old female patient, while U373 glioblastoma-astrocytoma cells are a
recognized
in vitro model of human malignant glioma. Both cells were maintained in
(50:50)
F12:DMEM medium supplemented with 10% fetal calf serum (FCS) and antibiotics
in a
humidified, 5% CO2 environment. Cells were passaged as required by
trypsinization.
[00791 Assays conditions: The effects of the test compounds were assessed
following
acute and chronic exposure conditions. For acute studies, cells were seeded in
96-well
plates in quadruplicate at a comparatively higher density (1X104 cells/well)
and
incubated with serial dilutions of the test compounds for 24 h prior to
analysis of cell
proliferation and/or viability. For chronic studies, cells were seeded at a
comparatively
lower density (2x103 cells/well) and incubated with the test compounds for 72
h. The test
compounds were evaluated over a broad range of concentrations (0, 0.5, 1, 5,
10, 50, 100
and 250 gimp with cells treated with equivalent concentrations of vehicle
(DMSO)
serving as controls.
[0080] Cell proliferation assay: Cell proliferation was assessed using a
standard
colorimetric indicator of metabolic activity (CIMA) assay. In this assay, the
reduction of
yellow tetrazolium salt (MTT) to purple formazan by mitochondrial reductase
enzymes
in viable cells was evaluated as a measure of metabolic activity to determine
the extent of
cell proliferation within a culture. The resulting colour change that
conferred a change in
absorbance was quantified using a spectrophotometer (--500-600). Samples were
diluted
as required to ensure that values obtained with the MTT assay fell within the
linear range
CA 02753513 2011-08-24
WO 2010/099600
PCT/CA2010/000281
23
of the protocol. Qualitative microscopic evaluation of treated cultures was
used to
determine if overt cytotoxicity was present and to supplement the quantitative
CIMA
data.
Results:
[0081] U373 astrocytoma cells: Neither overt cell death nor significant
reductions in
MTT activity were observed with compound I(a) or I(b) under acute and chronic
treatment conditions.
[0082] SH-5YSY neuroblastoma cells: Both compound I(a) and 1(b) produced an
approximately 30% decrease in MIT activity under acute treatment conditions at
a dose
of 0.25 mg/ml. No significant change in MTT activity was observed at the other
concentrations evaluated.
[0083] Under chronic treatment conditions, significantly decreased MTT
activity was
observed at 50, 100 and 250 1.1g/m1 doses. For compound I(a), this decrease
averaged
25% at each of the three concentrations. For compound I(b), maximal decreases
of 47%
were observed at the 250 [tg/m1 dose compared to 25% at 50 and 100 1.1g/m1
concentrations.
[0084] Analysis: Proof-of-principle studies indicate that neither compound
I(a) nor
compound I(b) exhibited profound cytostatic/cytotoxic activity in either of
the test cell
lines, although cell-specific differences in efficacy were observed. The
activity detected
was insufficient to estimate true LD50 concentrations for either compound. It
may be
concluded for the cell lines evaluated that the LD50 of compound I(a) exceeds
0.25
mg/ml in both acute and chronic regimens, while the LD50 of compound I(b) may
approach 0.25 mg/ml in select cell types under chronic conditions.
Example 4: Evaluation of the cytostatic and cytotoxic activity of test
compounds in a
diverse array of human neuroglioma and neuroblastoma cell lines
[0085] Compound preparation: Stock solutions of test compounds were prepared
in
dimethylsulfoxide (DMSO) at 250 mg/ml. Working concentrations of 10 mg/ml were
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
24
subsequently prepared from the stock solution and stored in 50 I aliquots at -
20 C until
used.
[0086] Cells and cell culture: Three classes of cells were evaluated: 1)
neuroblastoma
cells, 2) neuroglioma cells, and 3) non-transformed human neurons (see below).
All cells
were maintained in appropriate culture medium supplemented with 10% fetal calf
serum
(FCS) and antibiotics in a humidified, 5% CO2 environment. Cells were passaged
as
required by trypsinization.
[0087] Neuroglioma and Neuroblastoma cell lines:
Type: Designation Origin/Properties
Neuroblastoma I MR32 neuroblast from abdominal mass, male
NG108 neuroblastoma-neuroglioma fusion
NSC34 motor neuron, male
Neuroglioma U251 malignant glioma
U118 Grade 111 malignant astrocytoma, male
U138 Grade III malignant astrocytoma, male
D32 benign glioma
D37 benign glioma
TP483 malignant glioma
SW1088 astrocytoma, male
U87 Grade III malignant astrocytoma, female
Non-tumour HCN-1 cortical neuron (megalencephalic), male
HCN-2 cortical neuron (megalencephalic), male
[0088] Assay conditions: The effects of the test compounds were assessed
following
acute and chronic exposure conditions. For acute studies, cells were seeded in
96-well
4
plates in quadruplicate at a comparatively higher density (1X10 cells/well)
and
incubated with serial dilutions of the test compounds for 24 h prior to
analysis of cell
proliferation and/or viability. For chronic studies, cells were seeded at a
comparatively
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
lower density (2X103 cells/well) and incubated with test compounds for 72 h.
Each
compound was evaluated over a broad range of concentrations (0, 0.5, 1, 5, 10,
50, 100
and 250 gimp with cells treated with equivalent concentrations of vehicle
(DMSO)
serving as controls.
[0089] Cell proliferation assay: Cell proliferation was assessed using a
standard
colorimetric indicator of metabolic activity (CIMA) assay. In this assay, the
reduction of
yellow tetrazolium salt (MTT) to purple formazan by mitochondrial reductase
enzymes
in viable cells was evaluated as a measure of metabolic activity to determine
the extent of
cell proliferation within a culture. The resulting colour change that
conferred a change in
absorbance was quantified using a spectrophotometer (k=500-600). Samples were
diluted
as required to ensure that values obtained with the MTT assay fell within the
linear range
of the protocol. Qualitative microscopic evaluation of treated cultures was
used to
determine if overt cytotoxicity was present and to supplement the quantitative
C1MA
data.
Results:
Neurons:
[0090] In general, when effects were observed there were more pronounced
following
treatment with compound 1(a) than compound I(b). Cytostatic/cytotoxic effects
were
most commonly observed at the highest test concentration of 250 ttg/m1 at both
24 and 72
h post-treatment. Cytostatic/cytotoxic effects were only observed at 24 h post-
treatment
with this concentration. These observations applied to both transformed and
non-
transformed cells, suggesting that the effect was due to general toxicity
rather than a
tumour-specific process. Both compound I(a) and I(b) induced dose-dependent
decreases
in viability/proliferation for all three transformed neuronal cell lines at 72
h post-
treatment. These decreases were statistically significant but associated with
an LD50<
0.25 mg/ml only in the case of NSC34 motor neurons treated with compound I(a).
Astrocytes:
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
26
100911 As with neurons, when effects were observed they were generally more
pronounced following treatment with compound I(a) than compound 1(b).
Cytostatic/cytotoxic effects were most commonly observed at the highest test
concentration of 250 1.tg/ml. Decreases in viability/proliferation were
statistically
significant and associated with an LD50< 0.25 mg/ml only in the case of U87
and U138
cells. For both compounds, an LD50 < 0.1 mg/ml was not detected in any of the
cell lines
evaluated nor was an LD50 < 0.25 mg/ml detected in the acute treatment regimen
with
any cell line.
Example 5: Evaluation of the cytostatic and cyto toxic activity of test
compounds in a
broader spectrum of cancer cell types
100921 Compound preparation: Stock solutions of the test compounds were
prepared in
dimethylsulfoxide (DMSO) at 250 mg/ml. Working concentrations of 10 mg/ml were
subsequently prepared from the stock solution and stored in 50 [1.1 aliquots
at -20 C until
used.
100931 Cells and cell culture: Seven classes of tumours represented by a
minimum of two
different cell lines were evaluated: 1) breast, 2) lung, 3) colon, 4)
prostate, 5)
renal/hepatic, 6) ovarian/uterine, and 7) lymphoma cells (see below). Primary
human
dermal fibroblasts served as a representative non-transformed, non-cancerous
cell type.
All cells were maintained in appropriate culture medium supplemented with 10%
fetal
calf serum (FCS) and antibiotics in a humidified, 5% CO2 environment. Cells
were
passaged as required by trypsinization.
Tumour classes assayed:
Tumour Type Designation Origin/Properties
Breast BT-20 mammary gland carcinoma, female
BT-474 invasive ductal carcinoma, female
MCF-7 mammary gland adenocarcinoma
Lung H1299 metastatic non-small cell lung carcinoma, male
A549 lung carcinoma, male
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
27
Colon HT29 primary colorectal adenocarcinoma, female
HCT116 colorectal carcinoma, male
Prostate DU145 metastatic carcinoma, male
PC3 adenocarcinoma, male
Renal/Hepatic HepG2 hepatocellular carcinoma, male
786-0 renal cell adenocarcinoma, male
Ovarian/Uterine SK-O-V3 ovarian adenocarcinoma, female
OVCAR5 ovarian adenocarcinoma, female
Lymphoma TI IP-1 acute monocytic leukemia, male
U937 histiocytic lymphoma, male
SupT1 T lymphoblastic leukemia
Non-tumour CCD1079SK normal dermal fibroblast
[0094] Assay conditions: The effects of the test compounds were assessed
following
acute and chronic exposure conditions. For acute studies, cells were seeded in
96-well
4
plates in quadruplicate at a comparatively higher density (1X10 cells/well)
and
incubated with serial dilutions of the compound for 24 h prior to analysis of
cell
proliferation and/or viability. For chronic studies, cells were seeded at a
comparatively
lower density (2X103 cells/well) and incubated with the compound for 72 h.
Each
compound was evaluated over a broad range of concentrations (0, 0.5, 1, 5, 10,
50, 100
and 250 jig/m1) with cells treated with equivalent concentrations of vehicle
(DMSO)
serving as controls.
100951 Cell proliferation assay: Cell proliferation was assessed using a
standard
colorimetric indicator of metabolic activity (CIMA) assay. In this assay, the
reduction of
yellow tetrazolium salt (MTT) to purple formazan by mitochondrial reductase
enzymes
in viable cells was evaluated as a measure of metabolic activity to determine
the extent of
cell proliferation within a culture. The resulting colour change that
conferred a change in
absorbance was quantified using a spectrophotometer (X-500-600). Samples were
diluted
as required to ensure that values obtained with the MTT assay fell within the
linear range
CA 02753513 2011-08-24
WO 2010/099600
PCT/CA2010/000281
28
of the protocol. Qualitative microscopic evaluation of treated cultures was
used to
determine if overt cytotoxicity was present and to supplement the quantitative
CIMA
data.
[0096] Results: Both compound 1(a) and I(b) exhibited their most pronounced
effects in
lymphoma-derived cells, meeting the criteria of a change in MTT activity of 20-
30%
over a range of concentrations. Several other cell lines were similarly
affected at the
highest concentration of compound, but no specific pattern or preferential
inhibition of a
specific tumour cell type other than lymphomas was observed.
Example 6: Long Term Anti-cancer properties of compound 1(a)
[0097] Compound preparation: Stock solutions of the test compound were
prepared in
dimethylsulfoxide (DMSO) at 250 mg/ml. Working concentrations of 10 mg/ml were
0
subsequently prepared from the stock solution and stored in 50 jul aliquots at
-20C until
used. Compound I(a) was termed CMPD A (LI568-026-02).
[0098] Cells and cell culture: Two human brain cancer cell lines were used in
the study:
SH-SY5Y neuroblastoma cells and U373 astroglioma cells. Both cell lines were
maintained in appropriate culture medium supplemented with 10% fetal calf
serum
(FCS) and antibiotics in a humidified, 5% CO2 environment. Cells were passaged
as
required by trypsinization.
[0099] Assay conditions: The effects of the test compound were assessed under
long
term exposure conditions. Cells were propagated as normal in T25 flasks in
complete
culture media supplemented with comparatively low concentrations of the
compound (0,
1 and 5 pg/ml) for 28 days. At various times post-exposure, changes in
proliferation rates
were assessed using a standard CIMA assay.
[00100] Cell proliferation assay: Cell proliferation/viability was assessed
by
standard tetrazole reduction assay, a measure of metabolic function that
evaluates
mitochondrial activity to determine the extent of cell proliferation or
viability within a
culture. The resulting colour change that conferred a change in absorbance was
quantified using a spectrophotometer (k=500-600). Samples were diluted as
required to
CA 02753513 2011-08-24
WO 2010/099600
PCT/CA2010/000281
29
ensure that values obtained with the MTT assay fell within the linear range of
the
protocol. Qualitative microscopic evaluation of treated cultures was used to
determine if
overt cytotoxicity was present and to supplement the quantitative CIMA data.
For the
current study, cells that have been exposed to the compound were seeded in 96-
well
plates and proliferation rates measured over 24 and 72 h periods for
comparison to that of
similarly aged untreated cells.
[00101] Results: Data for the two cell lines is represented graphically in
Figure 1
with additional data in Table 1. As with the shorter term trials (Examples 2-
4), neither of
the test concentrations proved to be a 50% lethal dose (EDO. Both cell lines,
however,
did respond to compound I(a) in a similar manner and exhibited an average
decrease in
activity of approximately 20%. Although relatively limited, this decrease was
statistically
significant. Of note, differences between the two concentrations, or between
incubation
periods, were minimal. The cells disintegrated after several days and the cell
kill was
throughout the cell cycle, including Go.
Example 7: Evaluation of the anti-influenza activity of test compounds
[00102] Compound preparation: Stock solutions of the test compounds were
prepared in dimethylsulfoxide (DMSO) at 250 mg/ml. Working concentrations of
10
mg/ml were subsequently prepared from the stock solution and stored in 50111
aliquots at
0
-20C until used. The test compounds were compound I(a) and I(b) and had
molecular
structures as identified below.
[00103] Cells and viruses: Both primary chicken embryonic fibroblasts (CEF)
and
Madin-Darby canine kidney (MDCK) cells were evaluated in this study. Both cell
lines
produced similar results in preliminary trials; therefore, MDCK cells were
selected for
subsequent experiments. Both cells were maintained in the appropriate culture
medium
supplemented with 10% fetal calf serum (FCS) and antibiotics in a humidified,
5% CO2
environment. Cells were passaged as required by trypsinization. For infection,
cells were
cultured in serum-free, minimum essential medium (MEM) supplemented with BSA
and
CA 02753513 2011-08-24
WO 2010/099600
PCT/CA2010/000281
trypsin. Two strains of influenza were evaluated: 1) Influenza A (strain
A/PR/8/34), a
tissue culture adapted H1N1 serotype; and 2) Influenza B (strain B/Lee/40).
Both viruses
are tissue-cultured adapted to support an in vitro assay format.
[00104] Assay conditions: The effects of both compounds were assessed in a
prophylactic regimen in which cells were pre-treated with a serial dilution of
the test
compound (0, 0.5, 1, 5, 10, 25, 50 and 100 ug/m1) for 24 h prior to infection.
For assay,
4
MDCK cells (3X10 cells/well) were seeded in triplicate wells of 24-well
culture plates
and grown to 80% confluence, Cells were pre-treated with the test compound for
24 hr
prior to infection, washed and then incubated with 500 I of infection medium
0
(MOI=0.1) for 4h at 37C. Cells were again washed and then overlaid with 1%
agar
containing the test compound. Cytopathic effects (CPE) indicative of virus
replication
were visually evaluated over a one week time-course. Consistent with
literature reports,
CPE were easily detected with 48 hpi; thus, time-frames for replicate
experiments were
shortened to 48 h. CPE were evaluated by microscopy and the extent of damage
to the
monolayer scored according to a graduated scale where 1 indicated little or no
damage
and 6 indicated complete loss of monolayer integrity (Table 2). Individual
infections
were repeated in four independent trials.
[00105] Cytotoxicity assay: Cells were incubated with test compound for 24
or 72
h prior to evaluation of cell viability. Cytotoxicity was assessed using a
standard
colorimetric indicator of metabolic activity (CIMA) assay. In this assay, the
reduction of
yellow tetrazolium salt (MTT) to purple formazan by mitochondrial reductase
enzymes
in viable cells was evaluated as a measure of metabolic activity to determine
the extent of
cell proliferation within a culture. The resulting colour change that
conferred a change in
absorbance was quantified using a spectrophotometer (2=500-600). Samples were
diluted
as required to ensure that values obtained with the MTT assay fell within the
linear range
of the protocol. Qualitative microscopic evaluation of treated cultures was
used to
determine if overt cytotoxicity was present and to supplement the quantitative
CIMA
data.
CA 2753513 2017-04-04
31
[00106] Results:
The results of the study are summarized in Table 3. In general,
treatment with comparatively lower concentrations of I(a) resulted in a mild
to moderate
reduction in CPE following infection with either Influenza A or B strains.
This effect was
more prominent with the Influenza A strain than with Influenza B, and most
evident
earlier in the infection time-course. At least part of the increased CPE
observed with
concentrations of Compound A >25 ig/m1 may be attributed to toxicity
associated with
the compound itself at these higher concentrations (Table 4).
[00107] The results
obtained with I(b) mirrored that of I(a) in that lower
concentrations more greatly reduced CPE following Influenza A infection, and
in that
this reduction was greater at 24 hpi than at 48 hpi. However, I(b) treatment
had little
impact on CPE following Influenza B infection and did not evidence
cytotoxicity at
higher concentrations.
[00108] While the
present application has been described with reference to
what are presently considered to be the preferred examples, it is to be
understood that the
application is not limited to the disclosed examples. To the contrary, the
application is
intended to cover various modifications and equivalent arrangements included
within the
spirit and scope of the appended claims.
t= ________________________________________________
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
32
TABLE 1
U373 AVERAGE
24h 72h
0 jig/m1 1 jig/m1 5 g/ml 0 [Tim' 1 g/ml 5 g/ml
14 d - 0.569 0.446 0.437 - -
21 d 0.617 0.575 0.539 0.547 0.502 0.478
28 d 0.567 0.510 0.461 0.598 0.507 0.514
SD
24h 72h
0 jig/m1 1 jig/m1 5 jig/m1 0 jig/m1 1 jig/m1
5 jig/m1
14 d 0.013 0.020 0.036 - - -
21 d 0.025 0.020 0.022 0.020 0.015 0.005
28 d 0.050 0.011 0.027 0.023 0.025 0.025
SHSY5Y AVERAGE
24h 72h
0 g/ml 1 [teml 5 jig/m1 0 ,g/m1 1 jig/m1
5 g/ml
14d 0.492 0.508 0.388- - -
21 d 0.307 0.311 0.277 0.300 0.268 0.269
28 d 0.601 0.597 0.531 0.489 0.389 0.423
SD
24h 72h
0 jig/m1 1 1..tg/m1 5 jig/m1 01.1g/m1 1 jig/m1
5 jig/m1
14 d 0.023 0.009 0.012- - -
21 d 0.011 0.008 0.006 0.008 0.011 0.015
28d 0.016 0.018 0.025 0.015 0.016 0.024
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
33
TABLE 2
Score CPE
Complete monolayer with few gaps or
dead cells
2 Some gaps
in the monolayer; dead cells
more evident
3 Increasing
number of gaps in the
monolayer concurrent with dead cells
4 Gaps
widely distributed throughout the
monolayer and of increasing size
Large holes forming as smaller gaps
merge; copious dead cells evident
6 Monolayer
integrity lost. Small islands
of attached cells amid predominantly
dead cells.
CA 02753513 2011-08-24
WO 2010/099600 PCT/CA2010/000281
34
TABLE 3
Conc. 24 hpi 48 hpi
( g/m1) Influenza A Influenza B Influenza A Influenza B
Compd Compd Compd Compd Compd Compd Compd Compd
1(a) 1(b) 1(a) 1(b) 1(a) 1(b) 1(a) 1(b)
Mock' 1 1 1 1 2 2 1 1
DMSO 2 1 1 1 1 2 2 1 1
virus 3 3 4 4 4 4 5 5
alone 3
Virus + 3 3 4 4 4 4 4 4
DMSO 4
0.5 15 1 3 3 4 2 3 3
1.0 1 1 3 4 3 2 3 4
5.0 1 1 2 4 3 3 3 4
1 3 2 3 3 4 3 4
25 1 3 4 4 3 4 4 4
50 3 3 4 3 5 4 5 3
100 4 3 5 4 5 4 6 3
1. mock: untreated and uninfected cells
2. DMSO: uninfected cells pre-treated with vehicle alone (1%)
3, virus alone: untreated, influenza-infected cells
4. virus+DMSO: cells pre-treated with vehicle (1%) then infected with
influenza
5. bold: CPE in wells pre-treated with Compound 1(a) or 1(b) was less then
that observed in
controls
CA 02753513 2011-08-24
WO 2010/099600
PCT/CA2010/000281
TABLE 4
Conc. Compound 1(a) Compound 1(b)
(m/m1) 24hi 72h 24h 72h
0 1.112 1.11 1.01 1.00
0.5 1.09 1.05 1.02 0.99
1.0 1.24 0.99 1.07 1.00
5.0 1.18 1.15 1.09 0.94
10 1.15 1.01 1.00 0.97
25 1.06 0.96 1.08 1.04
50 1.08 0.713 1.13 0.99
100 0.98 0.56 1.09 0.89
1. Toxicity was evaluated after 24 or 72h of exposure to the test compound
to MDCK
cells
2. Values are expressed as fold changes relative to vehicle controls
3. Bold: decreases exceeding 25% of control values are considered to be a
toxic
response
